Ultragenyx Pharmaceutical Inc(RARE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RARE Ultragenyx Pharmaceutical Inc

盘后交易 12-23 19:00:00 EST

34.13

-0.62

-1.78%

盘后34.15

+0.02+0.06%

17:29 EST

最高34.89	最低34.07	成交量84.13万
今开34.73	昨收34.75	日振幅2.36%
总市值32.93亿	流通市值31.67亿	总股本9,648万
成交额2,888万	换手率0.91%	流通股本9,279万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RARE","market":"US","secType":"STK","nameCN":"Ultragenyx Pharmaceutical Inc","latestPrice":34.13,"timestamp":1766523600000,"preClose":34.75,"halted":0,"volume":841289,"hourTrading":{"tag":"盘后","latestPrice":34.15,"preClose":34.13,"latestTime":"17:29 EST","volume":31548,"amount":1076761.191528,"timestamp":1766528994453},"delay":0,"floatShares":92794919,"shares":96477569,"eps":-5.942723,"marketStatus":"盘后交易","change":-0.62,"latestTime":"12-23 19:00:00 EST","open":34.73,"high":34.89,"low":34.07,"amount":28883416.621104,"amplitude":0.023597,"askPrice":34.8,"askSize":57,"bidPrice":33.5,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-5.942723,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1766538000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1391144400000,"exchange":"NASDAQ","adjPreClose":34.75,"preHourTrading":{"tag":"盘前","latestPrice":34.6,"preClose":34.75,"latestTime":"09:12 EST","volume":1950,"amount":68177.4132,"timestamp":1766499154778},"postHourTrading":{"tag":"盘后","latestPrice":34.15,"preClose":34.13,"latestTime":"17:29 EST","volume":31548,"amount":1076761.191528,"timestamp":1766528994453},"volumeRatio":0.438408,"impliedVol":1.5233,"impliedVolPercentile":0.976},"requestUrl":"/m/hq/s/RARE","defaultTab":"news","newsList":[{"id":"2589828371","title":"数据：RARE 2小时小涨超 11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589828371","media":"链捕手","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589828371?lang=zh_cn&edition=full","pubTime":"2025-12-06 17:30","pubTimestamp":1765013429,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据币安现货数据显示，市场出现大幅波动。RARE 2小时涨幅达 11.32%。此外，ARDR 触及今日新低，跌幅为 7.15%；EGLD、LSK、PYR、CYBER、RED、RESOLV 和 WAL 均出现“冲高回落”状态，跌幅分别为 6.82%、5.29%、6.57%、5.41%、8.38% 和 6.81%。 ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2226873","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"2584590909","title":"数据：多个代币出现冲高回落，RARE 跌超 12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584590909","media":"链捕手","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584590909?lang=zh_cn&edition=full","pubTime":"2025-11-20 11:30","pubTimestamp":1763609434,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据币安现货数据显示，市场出现多种动态。CHR 涨幅为 6.92%，同时触及探底回升状态，ONE 涨幅为 6.49%，同样触及探底回升状态。另一方面，FET 出现“冲高回落”状态，跌幅为 5.7%。FIS、ILV 和 RARE 也分别出现“冲高回落”状态，跌幅为 10.61%、10.53% 和 12.83%。PYR 的跌幅更是达到 23.99%。 ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2222062","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RARE"],"gpt_icon":0},{"id":"1113313764","title":"异动解读 | Ultragenyx盘中大跌11.89%，4亿美元出售Crysvita特许权使用费引发投资者担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1113313764","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113313764?lang=zh_cn&edition=full","pubTime":"2025-11-05 22:43","pubTimestamp":1762353801,"startTime":"0","endTime":"0","summary":"罕见疾病制药公司Ultragenyx Pharmaceutical Inc今日盘中大跌11.89%，引发市场广泛关注。这一显著跌幅主要源于公司最新宣布的一项重大交易决策。据悉，Ultragenyx将其在Crysvita公司未来25%的特许权使用费权益以4亿美元的价格出售给加拿大养老基金OMERS。Crysvita是一种用于治疗罕见骨病的药物，自2018年获批以来，在相关地区的累计销售额已超过40亿美元。这笔交易引发了投资者对Ultragenyx长期收益前景的担忧。值得注意的是，Ultragenyx股价今年以来已下跌23%，此次下跌进一步加剧了投资者的忧虑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RARE"],"gpt_icon":0},{"id":"1165015812","title":"异动解读 | Ultragenyx盘前大跌11.83%，4亿美元出售Crysvita特许权使用费引发投资者担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1165015812","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165015812?lang=zh_cn&edition=full","pubTime":"2025-11-05 21:10","pubTimestamp":1762348250,"startTime":"0","endTime":"0","summary":"罕见疾病制药公司Ultragenyx Pharmaceutical Inc今日盘前大跌11.83%，引发市场广泛关注。这一跌幅主要源于公司最新宣布的一项重大交易决策。据悉，Ultragenyx将其在Crysvita公司未来25%的特许权使用费权益以4亿美元的价格出售给加拿大养老基金OMERS。Crysvita是一种用于治疗罕见骨病的药物，自2018年获批以来，在相关地区的累计销售额已超过40亿美元。这笔交易引发了投资者对Ultragenyx长期收益前景的担忧。值得注意的是，Ultragenyx股价今年以来已下跌23%，此次下跌进一步加剧了投资者的忧虑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RARE"],"gpt_icon":0},{"id":"1143181614","title":"异动解读 | Ultragenyx夜盘大跌13.68%，4亿美元出售Crysvita特许权使用费引发担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1143181614","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143181614?lang=zh_cn&edition=full","pubTime":"2025-11-05 09:19","pubTimestamp":1762305557,"startTime":"0","endTime":"0","summary":"罕见疾病制药公司Ultragenyx Pharmaceutical Inc在夜盘交易中股价大幅下跌13.68%，引发市场广泛关注。导致股价下跌的主要原因是公司宣布将其在Crysvita公司未来25%的特许权使用费权益以4亿美元的价格出售给加拿大养老基金OMERS。Crysvita是一种用于治疗罕见骨病的药物，自2018年获批以来，在相关地区的累计销售额已超过40亿美元。值得注意的是，Ultragenyx股价今年以来已下跌23%，此次下跌进一步加剧了投资者的忧虑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RARE"],"gpt_icon":0},{"id":"1192009820","title":"异动解读 | Ultragenyx盘后暴跌14.36%，4亿美元出售Crysvita特许权使用费引发担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1192009820","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192009820?lang=zh_cn&edition=full","pubTime":"2025-11-05 06:47","pubTimestamp":1762296453,"startTime":"0","endTime":"0","summary":"罕见疾病制药公司Ultragenyx Pharmaceutical Inc在盘后交易中股价大幅下跌14.36%，引发市场关注。根据公司公告，Ultragenyx将其在Crysvita公司未来25%的特许权使用费权益以4亿美元的价格出售给加拿大养老基金OMERS。根据协议，OMERS将从2028年1月开始从Crysvita在美国和加拿大的销售中获得额外的特许权使用费份额。Crysvita是一种用于治疗罕见骨病的药物，自2018年获批以来，在相关地区的累计销售额已超过40亿美元。值得注意的是，Ultragenyx股价今年以来已下跌23%，此次下跌进一步加剧了投资者的忧虑。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RARE"],"gpt_icon":0},{"id":"1166002991","title":"Ultragenyx出售Crysvita®（Burosumab）未来北美部分特许权使用费，交易金额为4亿美元，购买方为Omers Life Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=1166002991","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166002991?lang=zh_cn&edition=full","pubTime":"2025-11-05 05:02","pubTimestamp":1762290141,"startTime":"0","endTime":"0","summary":"Ultragenyx出售Crysvita®（Burosumab）未来北美部分特许权使用费，交易金额为4亿美元，购买方为Omers Life Sciences。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"1140084792","title":"Ultragenyx Pharmaceutical Inc - Omers将于2028年1月获得Crysvita额外25%的特许权使用费权益","url":"https://stock-news.laohu8.com/highlight/detail?id=1140084792","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140084792?lang=zh_cn&edition=full","pubTime":"2025-11-05 05:02","pubTimestamp":1762290131,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical Inc - Omers将于2028年1月获得Crysvita额外25%的特许权使用费权益","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"1114807797","title":"Ultragenyx宣布Aurora研究第一位患者接种Gtx-102，评估其他安吉尔曼综合征基因型及年龄组","url":"https://stock-news.laohu8.com/highlight/detail?id=1114807797","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114807797?lang=zh_cn&edition=full","pubTime":"2025-10-30 20:01","pubTimestamp":1761825679,"startTime":"0","endTime":"0","summary":"Ultragenyx宣布Aurora研究第一位患者接种Gtx-102，评估其他安吉尔曼综合征基因型及年龄组","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"1144166983","title":"新闻稿：Ultragenyx根据纳斯达克上市规则5635(c)(4)报告激励授予","url":"https://stock-news.laohu8.com/highlight/detail?id=1144166983","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144166983?lang=zh_cn&edition=full","pubTime":"2025-10-25 04:32","pubTimestamp":1761337953,"startTime":"0","endTime":"0","summary":"加利福尼亚州诺瓦托，2025年10月24日-- Ultragenyx Pharmaceutical Inc.，一家专注于稀有和超稀有疾病新疗法开发与商业化的生物制药公司，今天报告了向17名新聘非执行官授予20,317个限制性股票单位。该奖励已获得公司董事会薪酬委员会的批准，并根据Ultragenyx招聘激励计划授予，授予日期为2025年10月16日，作为新员工入职Ultragenyx的激励材料，符合纳斯达克上市规则5635。有关Ultragenyx的更多信息，请访问公司网站：www.ultragenyx.com。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNQmain","RARE","QID","QLD","TSYW.SI",".IXIC","NQmain","USJW.SI","NVIW.SI","USAW.SI","BK4139","PSQ","QQQ","TQQQ","SQQQ"],"gpt_icon":1},{"id":"1127687038","title":"Ultragenyx公布DTX401 AAV基因疗法治疗糖原储存病Ia型三期研究积极长期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1127687038","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1127687038?lang=zh_cn&edition=full","pubTime":"2025-09-09 04:05","pubTimestamp":1757361917,"startTime":"0","endTime":"0","summary":"Ultragenyx公布DTX401 AAV基因疗法治疗糖原储存病Ia型三期研究积极长期数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"2558681744","title":"Ultragenyx Pharmaceutical Inc.2025财年第二财季实现净利润-1.15亿美元，同比增加12.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558681744","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558681744?lang=zh_cn&edition=full","pubTime":"2025-08-11 00:01","pubTimestamp":1754841695,"startTime":"0","endTime":"0","summary":"8月11日，Ultragenyx Pharmaceutical Inc.公布财报，公告显示公司2025财年第二财季净利润为-1.15亿美元，同比增加12.88%；其中营业收入为1.66亿美元，同比增加12.93%，每股基本收益为-1.17美元。机构评级：截至2025年8月11日，当前有21家机构对Ultragenyx Pharmaceutical Inc.目标价做出预测，其中目标均价为84.62美元，其中最低目标价为34.00美元，最高目标价为128.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000348a6de081a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250811000348a6de081a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RARE"],"gpt_icon":0},{"id":"2557308749","title":"Ultragenyx Pharmaceutical Inc.盘中异动 大幅下跌5.05%报27.46美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557308749","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557308749?lang=zh_cn&edition=full","pubTime":"2025-08-06 22:11","pubTimestamp":1754489513,"startTime":"0","endTime":"0","summary":"北京时间2025年08月06日22时11分，Ultragenyx Pharmaceutical Inc.股票出现波动，股价大幅下跌5.05%。截至发稿，该股报27.46美元/股，成交量23.2957万股，换手率0.25%，振幅4.70%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体跌幅为0.02%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojorvi 和 Mepsevii。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508062211539737991d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508062211539737991d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RARE"],"gpt_icon":0},{"id":"2554720516","title":"派盾：SuperRare 遭遇攻击，损失约 73 万美元的 RARE","url":"https://stock-news.laohu8.com/highlight/detail?id=2554720516","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554720516?lang=zh_cn&edition=full","pubTime":"2025-07-28 17:41","pubTimestamp":1753695698,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据派盾监测，NFT 市场 SuperRare 遭遇攻击，损失价值约 73 万美元的 RARE 代币。 ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2193759","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"2554727850","title":"PeckShield：SuperRare遭遇攻击，损失约73万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554727850","media":"金色财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554727850?lang=zh_cn&edition=full","pubTime":"2025-07-28 17:34","pubTimestamp":1753695275,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://x.com/PeckShieldAlert/status/1949764035408527414","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinse_live","symbols":["BK4139","RARE"],"gpt_icon":0},{"id":"2551193127","title":"Ultragenyx Pharmaceutical Inc.盘中异动 大幅跳水5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551193127","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551193127?lang=zh_cn&edition=full","pubTime":"2025-07-15 22:46","pubTimestamp":1752590772,"startTime":"0","endTime":"0","summary":"北京时间2025年07月15日22时46分，Ultragenyx Pharmaceutical Inc.股票出现异动，股价快速跳水5.06%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体跌幅为0.21%。其相关个股中，Kairos Pharma, Ltd.、Polyrizon Ltd.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 涨幅较大，Polyrizon Ltd.、60 Degrees Pharmaceuticals, Inc.、Kairos Pharma, Ltd.较为活跃，换手率分别为1532.47%、1504.37%、1067.98%，振幅较大的相关个股有Kairos Pharma, Ltd.、Polyrizon Ltd.、Protagenic Therapeutics Inc C/Wts 26/04/2026 ，振幅分别为109.47%、75.50%、66.39%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojorvi 和 Mepsevii。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071522461395439b1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071522461395439b1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RARE"],"gpt_icon":0},{"id":"2550966544","title":"Ultragenyx Pharmaceutical Inc.盘中异动 股价大跌5.02%报29.48美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550966544","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550966544?lang=zh_cn&edition=full","pubTime":"2025-07-12 02:53","pubTimestamp":1752260000,"startTime":"0","endTime":"0","summary":"北京时间2025年07月12日02时53分，Ultragenyx Pharmaceutical Inc.股票出现波动，股价快速下跌5.02%。截至发稿，该股报29.48美元/股，成交量324.902万股，换手率3.44%，振幅4.45%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体跌幅为0.43%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojorvi 和 Mepsevii。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712025320953f1bc8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712025320953f1bc8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RARE"],"gpt_icon":0},{"id":"2550265656","title":"Ultragenyx Pharmaceutical Inc.盘中异动 早盘股价大涨5.00%报41.39美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550265656","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550265656?lang=zh_cn&edition=full","pubTime":"2025-07-09 22:18","pubTimestamp":1752070724,"startTime":"0","endTime":"0","summary":"北京时间2025年07月09日22时18分，Ultragenyx Pharmaceutical Inc.股票出现异动，股价急速拉升5.00%。截至发稿，该股报41.39美元/股，成交量22.1636万股，换手率0.23%，振幅4.16%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体涨幅为1.28%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojorvi 和 Mepsevii。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709221844a4408d84&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709221844a4408d84&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RARE"],"gpt_icon":0},{"id":"2514693738","title":"Ultragenyx Pharmaceutical Inc.盘中异动 快速拉升5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514693738","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514693738?lang=zh_cn&edition=full","pubTime":"2025-02-27 02:31","pubTimestamp":1740594704,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日02时31分，Ultragenyx Pharmaceutical Inc.股票出现异动，股价快速上涨5.02%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体跌幅为0.53%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。Mepsevii 适用于儿童和成人患者，用于治疗粘多糖贮积症 VII。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227023144a2552d5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227023144a2552d5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RARE","BK4139"],"gpt_icon":0},{"id":"2512654151","title":"Ultragenyx Pharmaceutical Inc.盘中异动 早盘股价大涨5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512654151","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512654151?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:42","pubTimestamp":1739889762,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时42分，Ultragenyx Pharmaceutical Inc.股票出现波动，股价急速拉升5.00%。Ultragenyx Pharmaceutical Inc.股票所在的生物技术行业中，整体涨幅为0.55%。其相关个股中，Solid Biosciences Inc.、Revolution Medicines Inc C/Wts 17/12/2026 、Pulmatrix, Inc.涨幅较大，Aditxt, Inc.、Solid Biosciences Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为303.06%、107.94%、86.68%，振幅较大的相关个股有Jasper Therapeutics Inc C/Wts 24/09/2026 、Conduit Pharmaceuticals Inc.、Pulmatrix, Inc.，振幅分别为34.04%、26.83%、23.16%。Ultragenyx Pharmaceutical Inc.公司简介：Ultragenyx Pharmaceutical Inc 是一家总部位于美国的生物制药公司。该公司的药品组合包括 Crysvita、Dojolvi 和 Mepsevii。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502182242429889ff3e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502182242429889ff3e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RARE"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ultragenyx.com","stockEarnings":[{"period":"1week","weight":-0.0409},{"period":"1month","weight":0.0345},{"period":"3month","weight":0.2236},{"period":"6month","weight":-0.0716},{"period":"1year","weight":-0.2142},{"period":"ytd","weight":-0.174}],"compareEarnings":[{"period":"1week","weight":0.006},{"period":"1month","weight":0.0391},{"period":"3month","weight":0.0326},{"period":"6month","weight":0.128},{"period":"1year","weight":0.1585},{"period":"ytd","weight":0.1685}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Ultragenyx Pharmaceutical Inc.于2010年4月22日成立，是一家处于发展阶段的生物科技企业，公司随后于2011年6月在特拉华州重新注册成立。公司专注于新型产品的鉴定、收购、开发与商业化，该产品主要用于治疗罕见和极罕见的疾病，产品最初目标是用于治疗严重的，令人衰弱的代谢基因类疾病。公司目前用于治疗遗传性包涵体肌病患者的缓释唾液酸正处于临床试验第二阶段，该疾病是一种渐进式的肌肉萎缩疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.014805},{"month":2,"riseRate":0.583333,"avgChangeRate":0.072766},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.056113},{"month":4,"riseRate":0.333333,"avgChangeRate":0.004951},{"month":5,"riseRate":0.416667,"avgChangeRate":0.029499},{"month":6,"riseRate":0.75,"avgChangeRate":0.064977},{"month":7,"riseRate":0.416667,"avgChangeRate":0.000441},{"month":8,"riseRate":0.583333,"avgChangeRate":0.035143},{"month":9,"riseRate":0.25,"avgChangeRate":-0.054828},{"month":10,"riseRate":0.25,"avgChangeRate":-0.056376},{"month":11,"riseRate":0.5,"avgChangeRate":0.037007},{"month":12,"riseRate":0.583333,"avgChangeRate":0.043969}],"exchange":"NASDAQ","name":"Ultragenyx Pharmaceutical Inc","nameEN":"Ultragenyx Pharmaceutical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ultragenyx Pharmaceutical Inc(RARE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ultragenyx Pharmaceutical Inc(RARE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ultragenyx Pharmaceutical Inc,RARE,Ultragenyx Pharmaceutical Inc股票,Ultragenyx Pharmaceutical Inc股票老虎,Ultragenyx Pharmaceutical Inc股票老虎国际,Ultragenyx Pharmaceutical Inc行情,Ultragenyx Pharmaceutical Inc股票行情,Ultragenyx Pharmaceutical Inc股价,Ultragenyx Pharmaceutical Inc股市,Ultragenyx Pharmaceutical Inc股票价格,Ultragenyx Pharmaceutical Inc股票交易,Ultragenyx Pharmaceutical Inc股票购买,Ultragenyx Pharmaceutical Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ultragenyx Pharmaceutical Inc(RARE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ultragenyx Pharmaceutical Inc(RARE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}